3White TC,Marr KA,Bowden RA.Clinical,cellular,and molecular factors that contribute to antifungal drug resistance.Clin Microbiol Rev,1998,11:382-402.
4Marichal P,Koymans L,Willemsens S,et al.Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg1 1 p,Cyp51p) to azole resistance in Candida albicans.Microbiology,1999,145:2701-2713.
5Wang WL,Li RY,Wang DL,et al.Resistant mechanisms of Candida albicans to fluconazole.J Chin Med,1999,112:466-471.
6Sanglard D,Ischer F,Koymans L,et al.Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.Antimicrob Agents Chemother,1998,42:241-253.
7White C.The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha-demethylase in Candida albicans.Antimicrob Agents Chemother,1997,41:1488-1494.
8Franz R,Kelly SL,Lamb DC,et al.Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.Antimicrob Agents Chemother,1998,42:3065-3072.
9Kakeya H,Miyazaki Y,Miyazaki H,et al.Genetic analysis of azole resistance in the Darlington strain of candida albicans.Antimicrob Agents Chemher,2000,44:2985-2990.
10Mi-Kyung Lee,Laura E.Williams,David W,et al.Drug resistance genes and trailing growth in Candida albicans isolates.Antimicrob Agents Chemother,2004,53:217-224.
